April 9, 2021
As the cell and gene therapy sector runs out of buyers, it runs into trouble (just like a fire that runs out of wood).
News: Cellectis SA (CLLS) completed sales of approximately $47 million of American Depositary Shares (ADS) pursuant to the Company’s ATM program <read more>
Pre-open indications: 3 BUYs, 5 SELLs and 1 Maintain SELL
Mentions: BSTG, BLFS, CLLS, IONS, NTLA, VCEL, FIXX, CRSP, EDIT
My version of the morning’s “numbers” is written to be informative rather than just about changes to share pricing; it’s what happened or will materialize beyond the opening and what might happen in the future
My comments are important in trying to distinguish the temporary from real pricing progress.
April 7, 2021
Biostage (BSTG) closed flat at $1.25 with 967 shares traded after Tuesday’s -$0.05 to $1.25 with 2008 shares traded, Monday’s -$0.04 to $1.30 with 2401 shares traded and last Thursday’s flat at 1.34 with 26 shares traded.
MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.
Maintaining Sell …
April 9, 2021
Investors expect higher volatility as Q1 ends but, we just finished reporting Q4 and FY10 as the sector shows little concern for fundamentals
Pre-open indication results: 7 HIT and 2 Miss
The sector is what it is, until it isn’t and even then, it doesn’t seem to be …
The week in review
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors
Where are the canaries in the sector coal mine, am I the only one?
April 7, 2021
Biostage (BSTG) closed flat at $1.25 with 967 shares traded after Tuesday’s -$0.05 to $1.25 with 2008 shares traded, Monday’s -$0.04 to $1.30 with 2401 shares traded and last Thursday’s flat at 1.34 with 26 shares traded. MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS. Maintaining Sell …
April 7, 2021
FIXX closed down -$0.34 or -3.53% to $9.30 With a -$1.57 or -16.88% pre-market indication to $7.73
April 6, 2021
Closed up +$0.41 or +0.88% to $47.25 With a negative -$2.45 or -5.19% aftermarket indication to $44.80
April 9, 2021
RegMed Investors’ (RMi) closing bell: just another sector beat-down
April 9, 2021
RegMed Investors’ (RMi) pre-open: trust, confidence versus conviction
April 8, 2021
RegMed Investors’ (RMi) closing bell: backup today, reversing yesterday’s algorithmic curse
April 8, 2021
RegMed Investors’ (RMi) pre-open: how now brown cow?
April 7, 2021
The Biostage (BSTG) Chronicles: Questions continue without any answers to date
April 7, 2021
RegMed Investors’ (RMi) closing bell: barely any distance in the upside
April 7, 2021
Homology Medicines (FIXX) prices $50 million offering at $7.90
April 7, 2021
RegMed Investors’ (RMi) pre-open: share pricing exhibits a streaking on the field anticipating a tackling
April 6, 2021
Ionis Pharmaceuticals (IONS) proposed $500 million private placement of Convertible Senior Notes
April 6, 2021
RegMed Investors’ (RMi) closing bell: what’s being shaken in today’s sector?
April 6, 2021
RegMed Investors’ (RMi) pre-open: what’s normal in this market?
April 5, 2021
RegMed Investors’ (RMi) closing bell: sector didn’t trend far from Thursday’s highs
April 5, 2021
RegMed Investors’ (RMi) closing bell: sector didn’t trend far from Thursday’s highs
April 5, 2021
RegMed Investors’ (RMi) closing bell: sector didn’t trend far from Thursday’s highs
April 5, 2021
RegMed Investors’ (RMi) pre-open: what and where will the demand for increased share pricing come from?
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
